GSE134837
Profiling non-small cell lung carcinoma cell line HCC827 treated with erlotinib
The non-small cell lung carcinoma (NSCLC) HCC827 cell line is an established preclinical model for tyrosine kinase inhibitors. To be able to better understand the differences in response between individual cells, we performed treatment of HCC827 cells grown in cell culture with erlotinib followed by Drop-seq. We were able to clearly distinguish cells that were treated with the drug from untreated cells, and we discovered different cell populations within the treated cells, likely reflecting heterogeneity of drug resistant cells. We were able to identify specific biomarkers, as preferentially expressed genes, for each cell population. The results of our study will address preexisting and acquired drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC. Overall design: Examining drug resistant cell populations using single cell RNA-seq